Acute Hepatic Porphyria Ahp Epidemiology Forecast

DelveInsight's "Acute Hepatic Porphyria (AHP) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Acute Hepatic Porphyria (AHP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Acute Hepatic Porphyria (AHP) Understanding

The DelveInsight Acute Hepatic Porphyria (AHP) epidemiology report gives a thorough understanding of the Acute Hepatic Porphyria (AHP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Acute Hepatic Porphyria (AHP) in the US, Europe, and Japan. The report covers the detailed information of the Acute Hepatic Porphyria (AHP) epidemiology scenario in seven major countries (US, EU5, and Japan).

Acute Hepatic Porphyria (AHP) Epidemiology Perspective by DelveInsight

The Acute Hepatic Porphyria (AHP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Acute Hepatic Porphyria (AHP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Acute Hepatic Porphyria (AHP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Acute Hepatic Porphyria (AHP) Detailed Epidemiology Segmentation

The Acute Hepatic Porphyria (AHP) epidemiology covered in the report provides historical as well as forecasted Acute Hepatic Porphyria (AHP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

The DelveInsight Acute Hepatic Porphyria (AHP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Acute Hepatic Porphyria (AHP) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Acute Hepatic Porphyria (AHP) Epidemiology Report and Model provide an overview of the global trends of Acute Hepatic Porphyria (AHP) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Acute Hepatic Porphyria (AHP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Acute Hepatic Porphyria (AHP)
  • The report provides the segmentation of the Acute Hepatic Porphyria (AHP) epidemiology

Report Highlights

  • 11-year Forecast of Acute Hepatic Porphyria (AHP) epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Acute Hepatic Porphyria (AHP)
  • Cases of Acute Hepatic Porphyria (AHP) by Mutation Types
  • Acute Hepatic Porphyria (AHP) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Hepatic Porphyria (AHP)?
  • What are the key findings pertaining to the Acute Hepatic Porphyria (AHP) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Acute Hepatic Porphyria (AHP) across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Acute Hepatic Porphyria (AHP)?
  • What are the currently available treatments of Acute Hepatic Porphyria (AHP)?

Reasons to buy

The Acute Hepatic Porphyria (AHP) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Acute Hepatic Porphyria (AHP) market
  • Quantify patient populations in the global Acute Hepatic Porphyria (AHP) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acute Hepatic Porphyria (AHP) therapeutics in each of the markets covered
  • Understand the magnitude of Acute Hepatic Porphyria (AHP) population by its epidemiology
  • The Acute Hepatic Porphyria (AHP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Acute Hepatic Porphyria (AHP)

3. Acute Hepatic Porphyria (AHP): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in the 7MM (2019- 2032)

5.4. United States Epidemiology

5.4.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in the United States (2019- 2032)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in Germany (2019- 2032)

5.5.2. France Epidemiology

5.5.2.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in France (2019- 2032)

5.5.3. Italy Epidemiology

5.5.3.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in Italy (2019- 2032)

5.5.4. Spain Epidemiology

5.5.4.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in Spain (2019- 2032)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in the United Kingdom (2019-2032)

5.6. Japan Epidemiology

5.6.1. Acute Hepatic Porphyria (AHP) Epidemiology Scenario in Japan (2019- 2032)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Acute Hepatic Porphyria (AHP) Treatment and Management

6.2. Acute Hepatic Porphyria (AHP) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

List of Tables

Table 1:  Acute Hepatic Porphyria (AHP) Epidemiology in 7MM (2019-2032)

Table 2: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in 7MM (2019-2032)

Table 3: Acute Hepatic Porphyria (AHP) Epidemiology in the United States (2019-2032)

Table 4: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Acute Hepatic Porphyria (AHP) Epidemiology in Germany (2019-2032)

Table 6: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Acute Hepatic Porphyria (AHP) Epidemiology in France (2019-2032)

Table 8: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Acute Hepatic Porphyria (AHP) Epidemiology in Italy (2019-2032)

Table 10: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Acute Hepatic Porphyria (AHP) Epidemiology in Spain (2019-2032)

Table 12: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Acute Hepatic Porphyria (AHP) Epidemiology in the United Kingdom (2019-2032)

Table 14: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Table 15: Acute Hepatic Porphyria (AHP) Epidemiology in Japan (2019-2032)

Table 16: Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Japan (2019-2032)

List of Figures

Figure 1 Acute Hepatic Porphyria (AHP) Epidemiology in 7MM (2019-2032)

Figure 2 Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in 7MM (2019-2032)

Figure 3 Acute Hepatic Porphyria (AHP) Epidemiology in the United States (2019-2032)

Figure 4 Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5  Acute Hepatic Porphyria (AHP) Epidemiology in Germany (2019-2032)

Figure 6  Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7  Acute Hepatic Porphyria (AHP) Epidemiology in France (2019-2032)

Figure 8 Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in France (2019-2032)

Figure 9 Acute Hepatic Porphyria (AHP) Epidemiology in Italy (2019-2032)

Figure 10 Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11 Acute Hepatic Porphyria (AHP) Epidemiology in Spain (2019-2032)

Figure 12 Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13 Acute Hepatic Porphyria (AHP) Epidemiology in the United Kingdom (2019-2032)

Figure 14 Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Figure 15 Acute Hepatic Porphyria (AHP) Epidemiology in Japan (2019-2032)

Figure 16 Acute Hepatic Porphyria (AHP) Diagnosed and Treatable Cases in Japan (2019-2032)

*The table of contents is not exhaustive; will be provided in the final report

Forward to Friend

Need A Quote